Treatment Dilemmas in Disseminated Nontuberculous Mycobacterial Infections With Interferon-gamma Autoantibodies.
Elizabeth M KingVictoria K WeaverMary H KestlerPublished in: Open forum infectious diseases (2021)
Disseminated Mycobacterium avium complex (dMAC) is typically seen in individuals with impaired cell-mediated immunity and is best described in those with HIV. Recently, cases have been described in otherwise healthy individuals with neutralizing antibodies to interferon-gamma (nIFNγ-autoAb), especially in patients of Southeast Asian descent. Treatment is often refractory to mycobacterial therapies, and the use of rituximab and other immunomodulatory agents has been explored. We report 3 cases of dMAC with nIFN-γ-autoAb and review the available literature on treatment strategies to provide a framework for the management of patients with refractory infections in the context of neutralizing antibodies to interferon-gamma.
Keyphrases
- mycobacterium tuberculosis
- end stage renal disease
- dendritic cells
- ejection fraction
- systematic review
- chronic kidney disease
- hepatitis c virus
- human immunodeficiency virus
- diffuse large b cell lymphoma
- peritoneal dialysis
- stem cells
- prognostic factors
- dengue virus
- cell therapy
- immune response
- mesenchymal stem cells
- hiv testing
- patient reported outcomes
- replacement therapy
- patient reported